23andMe Announces Collaboration Extension with a New Data Licensing Agreement with GSK
30 Outubro 2023 - 9:00AM
23andMe Holding Co. (Nasdaq: ME) (“23andMe”) today announced a new,
non-exclusive data license with GSK plc (LSE/NYSE: GSK) which
extends their collaboration and enables GSK to conduct drug target
discovery and other research using the 23andMe database, the
world’s largest recontactable resource of genetic and phenotypic
information from consented participants. Under an amendment to
their Collaboration Agreement, 23andMe will receive a $20 million
upfront payment for a one year, non-exclusive data license. The
license will also include access to certain services such as
further analyses of the 23andMe data not provided in the core data
release.
“We’ve had an incredibly successful collaboration with GSK over
the past five years, and we are excited to continue our work
together,” said Anne Wojcicki, CEO and Co-Founder, 23andMe. “With
approximately 50 programs developed over the last five years, we
are thrilled to work with GSK in discovering genetically validated
targets. The continued relationship with GSK demonstrates the power
of the 23andMe research platform to consistently produce novel
insights for therapeutic development, rooted in human
genetics.”
Under terms of the new data license, 23andMe will provide GSK
with access to de-identified, summary data from global genome- and
phenome-wide analysis of the 23andMe database, for a 12-month
period, and offer its research services for analyses of the data
over that same period. Any new drug discovery programs that GSK
chooses to initiate during the agreement will be owned and advanced
solely by GSK. 23andMe may be eligible for downstream royalties
under certain uses of the database by GSK. As part of the
amendment, 23andMe is taking the royalty option on three programs
previously initiated by the two companies, which GSK will
independently advance, with 23andMe retaining certain rights to
downstream royalties. 23andMe and GSK both retain royalties on a
number of active programs developed under the initial
collaboration.
“The 23andMe research database is constantly growing, which
increases its power for therapeutic research over time,” said Adam
Auton, Vice President, Human Genetics at 23andMe. “We’ve also made
significant strides to increase the power of our database by
improving our imputation technology, utilizing whole genome
sequencing data to dramatically increase the number of genetic
variants that we’re able to interrogate. In addition, we continue
to expand our capabilities in deep phenotyping, artificial
intelligence and machine learning, rare disease research, and
developing recontactable cohorts in specific disease areas, all
with the objective of more efficiently identifying drug targets
that will hopefully be developed into new medicines.”
About 23andMe23andMe is a genetics-led consumer
healthcare and biopharmaceutical company empowering a healthier
future. For more information, please visit www.23andMe.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, including, without limitation, statements regarding the
future performance of 23andMe’s businesses in consumer genetics and
therapeutics and the growth and potential of its proprietary
research platform. All statements, other than statements of
historical fact, included or incorporated in this press release,
including statements regarding 23andMe’s products, strategy,
financial position, funding for continued operations, cash
reserves, projected costs, plans, potential future collaborations,
therapeutics development, database growth, product development and
launches, the successful commercialization and market acceptance of
new products and objectives of management, are forward-looking
statements. The words "believes," "anticipates," "estimates,"
"plans," "expects," "intends," "may," "could," "should,"
"potential," "likely," "projects," "predicts," "continue," "will,"
"schedule," and "would" or, in each case, their negative or other
variations or comparable terminology, are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. These forward-looking
statements are predictions based on 23andMe’s current expectations
and projections about future events and various assumptions.
23andMe cannot guarantee that it will actually achieve the plans,
intentions, or expectations disclosed in its forward-looking
statements and you should not place undue reliance on 23andMe’s
forward-looking statements. These forward-looking statements
involve a number of risks, uncertainties (many of which are beyond
the control of 23andMe), or other assumptions that may cause actual
results or performance to differ materially from those expressed or
implied by these forward-looking statements. The forward-looking
statements contained herein are also subject generally to other
risks and uncertainties that are described from time to time in the
Company’s filings with the Securities and Exchange Commission,
including under Item 1A, “Risk Factors” in the Company’s most
recent Annual Report on Form 10-K, as filed with the Securities and
Exchange Commission, and as revised and updated by our Quarterly
Reports on Form 10-Q and Current Reports on Form 8-K. The
statements made herein are made as of the date of this press
release and, except as may be required by law, 23andMe undertakes
no obligation to update them, whether as a result of new
information, developments, or otherwise.
Contacts: Investor Relations Contact:
investors@23andMe.comMedia Contact: press@23andMe.com
23andMe (NASDAQ:ME)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
23andMe (NASDAQ:ME)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024